Objectives: Therapeutic options in Clostridium difficile infection (CDI) are limited. We examined linezolid activity in vitro and potential therapeutic efficacy using a gut model of CDI.
Introduction
The incidence of Clostridium difficile infection (CDI) has increased in recent years, particularly disease attributed to an apparently hypervirulent C. difficile strain that has been identified as 027 by PCR ribotyping, NAP1 by PFGE and BI by restriction endonuclease analysis. 1 -4 CDI is a major financial burden upon healthcare systems worldwide; a recent report estimated that in the USA alone the annual costs associated with CDI were $3.4 billion. 5 CDI is almost exclusively associated with prior antimicrobial therapy and classes of antimicrobial agents with a noted predisposition for induction of CDI include lincosamides, aminopenicillins and cephalosporins (particularly third generation). 6 -8 Antimicrobial agents that induce CDI are hypothesized to perturb the stable colonic microflora, reduce host colonization resistance and thus facilitate C. difficile spore germination, proliferation and toxin production. Treatment strategies for CDI have changed little over the past two decades. Oral metronidazole (400 -500 mg three times daily) or vancomycin (125 mg four times daily) are most commonly used to treat CDI. 9 Early studies demonstrated little difference between metronidazole and vancomycin in terms of response or recurrence rates, although response time was faster with the latter. 10 -12 More recent reports have questioned the efficacy of metronidazole therapy for CDI, particularly for disease caused by epidemic C. difficile ribotype 027. 13, 14 These studies have reinforced the need to evaluate the efficacy of new antimicrobial agents for the treatment of CDI. We have used a triple-stage chemostat human gut model to investigate both antimicrobial induction 15 -19 and treatment of CDI. 20 -23 Linezolid is an oxazolidinone antimicrobial agent active principally against Gram-positive bacteria by inhibiting protein synthesis via targeting of bacterial 23S rRNA. 24 Linezolid is not currently used to treat CDI, but can inhibit exotoxin production, 25, 26 and has been reported to have good activity against C. difficile. 27, 28 Susceptibilities of 118 C. difficile isolates (including epidemic strains and isolates with reduced susceptibility to metronidazole 29 ) to linezolid were determined in a preliminary study using an agar incorporation method. We then examined the efficacy of linezolid in treating simulated CDI caused by epidemic C. difficile PCR ribotypes 027 and 106 in separate experiments using a triplestage chemostat human gut model.
Materials and methods

C. difficile strains
The C. difficile ribotype 027 strain evaluated in the in vitro human gut model was isolated during an outbreak of CDI at the Maine Medical Center (Portland, ME, USA) in 2005 and was supplied via Dr Robert Owens (Maine Medical Center). The C. difficile PCR ribotype 106 strain evaluated in the in vitro human gut model was isolated from a symptomatic female patient with CDI at the Leeds General Infirmary in 2007 (Leeds, UK). A total of 32 genotypically distinct C. difficile isolates (by PCR ribotyping), 11 each of the three most commonly encountered C. difficile PCR ribotypes in the UK (ribotypes 001, 106 and 027) and 22 C. difficile isolates with reduced susceptibility to metronidazole 29 were used in linezolid susceptibility studies. Linezolid susceptibilities of the epidemic C. difficile strains studied in prior gut model experiments were also determined, i.e. PCR ribotypes 001 (n¼1), 106 (n¼1) and 027 (n ¼2). PCR ribotyping was performed by Dr Warren N. Fawley [C. difficile Ribotyping Network for England and N. Ireland (CDRN), Leeds General Infirmary, Leeds, UK] using the method of Stubbs et al. 30 Additionally, linezolid MICs for 27 C. difficile PCR ribotype 023 faecal isolates recovered via the CDRN were determined.
Triple-stage chemostat human gut model
We have described previously the use of a triple-stage chemostat human gut model to study the interplay between antimicrobial agents, the indigenous gut microflora and C. difficile. 15 -23 The gut model was validated against physicochemical and microbiological measurements from the intestinal contents of sudden-death victims. 31 The gut model is, however, limited by an inability to simulate immunological and secretory events that occur within the human colon. The gut model comprised three pH-maintained (pH 5.5+0.1, vessel 1; pH 6.2+0.1, vessel 2; and pH 6.8+0.1, vessel 3) fermentation vessels, top-fed by growth medium at a controlled rate [dilution rate (D)¼0.015 h
21
]. Constituents and preparation of growth medium for the gut model were as described previously. 18 The gut model was inoculated with a faecal emulsion ( 10% w/v in pre-reduced PBS) prepared from C. difficile-negative faeces of five elderly (≥65 years) volunteers. Faecal donors were in good health and received no antimicrobial therapy for at least 3 months prior to commencement of this study.
Enumeration of gut microflora and C. difficile cytotoxin titres
Gut bacterial populations and C. difficile numbers were enumerated as described previously. 15 Gut microflora populations cultured were total facultative anaerobes, total anaerobes (facultative+obligate), lactosefermenting Enterobacteriaceae, enterococci, lactobacilli, bifidobacteria, total Clostridium spp., Bacteroides fragilis group, C. difficile total viable counts (vegetative C. difficile+spores) and C. difficile spore viable counts. C. difficile cytotoxin production was monitored using a Vero cell cytotoxicity assay as described previously. 18 Indigenous gut microflora populations from vessel 1 of the gut models were not determined; only C. difficile total viable counts, spore counts and cytotoxin titres were quantified. Additionally, C. difficile selective agar containing 4 mg/L linezolid was used to monitor selection for C. difficile PCR ribotype 106 or 027 resistant to linezolid once dosing of the drug commenced.
Experimental design
Time periods for this experiment are displayed in Figure 1 . Following inoculation of the gut model with faecal emulsion (day 0) the medium pump was started and no further interventions were made for 13 days. Gut microflora were enumerated every 2 days. C. difficile spores ( 10 7 cfu) were prepared as described previously 15 and inoculated into vessel 1 on day 14. Viable counts of C. difficile and the indigenous gut microflora and C. difficile cytotoxin titres were monitored daily thereafter. After 7 days another single inoculum of C. difficile spores was instilled into vessel 1 followed by 150 mg/L ceftriaxone once daily for 7 days. Ceftriaxone was instilled to reflect the concentration observed in faeces of patients and volunteers. 32 
Antimicrobial assay and MIC determination
Samples (1 mL) from each vessel of the gut model were centrifuged (15 min, 16000 g) and the supernatants sterilized by filtration through 0.22 mm syringe filters. Sterilized culture supernatants were stored at 2708C prior to antimicrobial assay. Linezolid concentrations were determined by large plate bioassay (Leeds) and by a previously validated HPLC method (BCARE Bristol 34 ). Chromatography was performed on a Hypersil 5ODS column (HPLC Technology Ltd, Macclesfield, UK) using a mobile phase of methanol/water/phosphoric acid (30:69:1) with the addition of 2 g/L heptane sulphonic acid (Sigma Chemical Co.) and the pH adjusted to 4.5. The assay response was linear over the concentration range 0.05-100 mg/L, with a lower limit of quantification of 0.1 mg/L for linezolid. Recovery was in the range 95%-110%, and intra-day accuracy and precision were assessed by the use of quality control standards with limits of accuracy of 10% (actual¼9.5%) and coefficient of variability for precision of ,5% (actual¼2.3%).
Microbiological bioassay
Spore suspensions ( 4×10 8 cfu/mL) of the indicator organism Bacillus subtilis ATCC 6633 were prepared to seed bioassay agar. Briefly, 30 mL volumes of LB broth were inoculated with a fresh (24 h) culture of B. subtilis ATCC 6633 and incubated at 358C for 48 h with continuous agitation. Cultures were centrifuged at 3000 g for 15 min, the supernatants discarded and the pellets alcohol shocked in 6 mL of 50% (v/v in saline) ethanol for at least 1 h. Spore preparations were stored at ambient temperature until required. B. subtilis spore suspension (500 mL) was added to 100 mL of molten Mueller-Hinton agar (508C), mixed by inversion and agar poured into 245 mm 2 bioassay dishes. Agars were allowed to set at room temperature, following which 25 wells (9 mm in diameter) were removed from the agar using a cork borer. Linezolid calibrators (30 mL, 4 -64 mg/L) and filter-sterilized samples from the gut model were randomly assigned to bioassay wells in triplicate. Bioassay plates remained at ambient temperature for 4 h before overnight aerobic incubation at 378C. Zone diameters were measured using calipers accurate to 0.1 mm. Calibration lines were plotted from squared zone diameters and unknown concentrations from culture supernatants determined. All assays were performed in duplicate. Coefficient of variation values were typically 15% for linezolid bioassays and R 2 values for calibration lines all .0.96. The limit of detection for the linezolid bioassay was 3 mg/L.
Linezolid MIC determination
Agar incorporation MICs were determined using previously published methods. 35 Antimicrobial agents evaluated in MIC studies were linezolid, metronidazole and vancomycin. All antimicrobial stock solutions were prepared in deionized water and sterilized by filtration through 0.22 mm syringe filters. Briefly, C. difficile strains were cultured in pre-reduced Schaedler's anaerobic broth overnight to an inoculum density of 10 8 cfu/mL and diluted 1:10 in sterile pre-reduced saline. One microlitre of diluted culture ( 10 4 cfu) was then applied to antimicrobialcontaining or control agar (Wilkins Chalgren agar) using a multipoint inoculator. Antimicrobial-containing plates and growth controls were incubated at 378C in an anaerobic atmosphere for 48 h. MICs were determined in duplicate for all antimicrobials. The MIC was determined as the antimicrobial concentration where an absence or marked reduction in growth (multiple tiny colonies, haze or fine film of growth or one or two colonies) compared with the growth control was observed. Linezolid MICs for an additional panel of C. difficile PCR ribotype 023 isolates (n ¼27) were also determined.
Results
Susceptibility of C. difficile to linezolid
Linezolid demonstrated overall equivalent activity to metronidazole and vancomycin against a large collection of clinical C. difficile isolates (Table 1) 
Equilibration period and internal C. difficile control period
In general, observations in vessels 2 and 3 of the gut model were very similar, and therefore we have concentrated on data from vessel 2 of each experiment in this report. The composition of the indigenous gut microflora in C. difficile PCR ribotype 027 and 106 gut models was similar, and both achieved steady-state by the end of period A. Indigenous gut microfloras were dominated by obligate anaerobes, e.g. B. fragilis group and bifidobacteria, Figure 2a and b).
Effects of ceftriaxone instillation
Instillation of ceftriaxone facilitated similar alterations in indigenous gut microflora composition in both gut models. A deleterious effect of ceftriaxone instillation against bifidobacteria (4 log 10 cfu/mL), B. fragilis group (2 log 10 cfu/mL), lactobacilli (2 log 10 cfu/mL) and lactose-fermenting Enterobacteriaceae (2 log 10 cfu/mL) was observed, although B. fragilis group viable counts increased again by the end of ceftriaxone instillation. Enterococcus spp. were unaffected by ceftriaxone instillation and viable counts increased by 2 log 10 cfu/mL by the end of ceftriaxone instillation. Following a second instillation of C. difficile spores concurrent to ceftriaxone instillation, C. difficile remained quiescent for 2 and 3 days, respectively, in the PCR ribotype 027 and 106 gut models (period C, Figure 2a and b) . A marked increase in C. difficile total viable count over spore count was observed after 3 and 4 days of ceftriaxone instillation, respectively, in the PCR ribotype 027 and 106 gut Baines et al. models. C. difficile total viable counts increased to 6.5 log 10 cfu/mL and stabilized at this concentration in both gut models for the remainder of the ceftriaxone instillation period. C. difficile cytotoxin was detected after 4 and 5 days of ceftriaxone instillation, respectively, in the PCR ribotype 106 and 027 gut models. By the end of ceftriaxone instillation C. difficile cytotoxin titres were 3 RU (PCR ribotype 106) and 4 RU (PCR ribotype 027). No C. difficile spore germination, proliferation or cytotoxin production was observed in vessel 1 of either gut model (data not shown).
Linezolid instillation
Instillation of linezolid commenced 2 days after cessation of ceftriaxone dosing in the C. difficile PCR ribotype 027 gut model (day 29) and 1 day later in the C. difficile PCR ribotype 106 gut model (day 30).
Concentrations of linezolid in the gut model
Linezolid was instilled into vessel 1 of the gut model at 7 mg/L twice daily, which according to theoretical mass balance calculations should have reached steady-state concentrations of 16.22 mg/L in vessel 1 of the gut model (calculations not shown). Linezolid was detectable in all vessels of the gut models using both assay methods (Figure 3a and b) . Linezolid concentrations demonstrated by microbiological bioassay were lower than those by HPLC. Peak linezolid concentrations in vessel 1 of the C. difficile PCR ribotype 027 gut model were substantially higher than those in vessels 2 and 3 and also the corresponding PCR ribotype 106 gut model. A malfunction of the growth medium pump in the C. difficile PCR ribotype 027 gut model (day 30/31) occurred, which may explain the markedly higher concentration of linezolid in vessel 1 of the gut model at that time. Consequently, linezolid was undetectable by HPLC in vessel 3 of the C. difficile PCR ribotype 027 gut model until 4 days after commencement of linezolid instillation, i.e. 2 days after linezolid was detected by HPLC in vessel 3 of the corresponding PCR ribotype 106 gut model. Peak linezolid concentrations were similar in vessels 2 and 3 of both gut models (Figure 3a and b) .
Effects of linezolid on gut microflora and C. difficile in the PCR ribotype 106 gut model
Linezolid instillation facilitated minor reductions in viable counts of Bifidobacterium spp., Lactobacillus spp. and Enterococcus spp., Linezolid and C. difficile infection model and more substantial declines of 2.5 and 3 log viable counts of Clostridium spp. and B. fragilis group, respectively (pre-dosing counts of 8 and 7.5 log cfu/mL, respectively). Lactose-fermenting Enterobacteriaceae viable counts showed a substantial 5.5 log 10 cfu/mL increase from 4.0 -5.1 log cfu/mL to 9.5 -9.9 log cfu/mL by the end of linezolid instillation. C. difficile total viable counts declined rapidly in vessels 2 and 3 of the gut model, with only C. difficile spore forms demonstrable 4 days after commencement of linezolid dosing (period E, Figure 2a and (Figure 4b ).
Effects of linezolid on gut microflora and C. difficile in the PCR ribotype 027 gut model
Alterations in viable counts of indigenous gut microfloras following commencement of linezolid instillation were similar to those observed in the PCR ribotype 106 gut model. The rate of decline in C. difficile total viable counts following instillation of linezolid was similar to that observed in an untreated ceftriaxone gut model study (Figure 4a ). C. difficile PCR ribotype 027 cytotoxin titres following linezolid instillation were undetectable 6 days earlier than those measured in an untreated ceftriaxone gut model study (Figure 4b ).
Observations following cessation of linezolid instillation
Viable counts of all the indigenous gut microfloras adversely affected by linezolid instillation recovered during the post-dosing recovery period in both gut models. Linezolid was undetectable (,3 mg/L) in vessels 1, 2 and 3 of the PCR ribotype 106 gut model 3, 4 and 6 days, respectively, after cessation of antibiotic instillation, as measured by bioassay ( Figure 3 ). Linezolid was undetectable in the PCR ribotype 027 gut model after 2, 1 and 3 days in vessels 1, 2 and 3, respectively, as measured by bioassay. Increased C. difficile PCR ribotype 106 total viable counts over spore counts were observed in vessels 2 and 3 of the gut model 9 days after cessation of linezolid instillation, and subsequently C. difficile cytotoxin was detectable (Figure 2a) . No additional cycle of growth and cytotoxin production was observed in the PCR ribotype 027 gut model following cessation of linezolid instillation (Figure 2b ). No C. difficile colonies were recovered from selective agars containing 4 mg/L linezolid during either linezolid instillation or the post-dosing recovery period.
Discussion
Linezolid had good activity against 98% of the C. difficile isolates in this study, reflecting prior susceptibility studies. 27, 28 Two C. difficile isolates (ribotypes 023 and 067) were resistant to linezolid (MIC ¼8 mg/L). Of these two PCR ribotypes, 023 accounted for 3% of CDI reports in a recent European study, while 067 is a very uncommon cause of CDI. 36 Evaluation of a further panel of C. difficile PCR ribotype 023 demonstrated no additional resistant isolates, and therefore linezolid resistance in C. difficile appears to be rare and not related to ribotype clones. Resistance to linezolid in C. difficile was first documented by Ackermann et al., 37 who showed low-level resistance (6 mg/L) in 6 of 192 clinical C. difficile isolates. This group reported elevated linezolid MICs associated with erythromycin and clindamycin resistance, and we also observed this in ribotypes 023 and 067 upon further investigation (MIC 128-.256 mg/L of both antimicrobials). However, in contrast to Ackermann et al. 37 both were susceptible to moxifloxacin (MIC 2 mg/L). Ackermann et al. 37 did not perform DNA typing on the C. difficile isolates, and therefore it is difficult to determine the epidemiological significance of the cross-resistance they described. Mechanisms of resistance to linezolid have been documented in some Gram-positive bacteria, 38, 39 but not in C. difficile, although linezolid MICs up to 24 mg/L have been reported. 28, 40 Failure to isolate C. difficile from gut model samples, collected during and after prolonged exposure, that were plated onto linezolid breakpoint agar, suggests there is a low propensity for resistance development via clonal selection. Indeed, Schmidt et al. 41 failed to select resistant C. difficile using an agar-based method over three bacterial generations. The acquisition/development of linezolid resistance in C. difficile using other experimental techniques warrants further study especially if linezolid may be considered a potential treatment for CDI in the future.
In the present gut model experiments we used ceftriaxone to induce C. difficile spore germination, proliferation and high-level cytotoxin production, as previously demonstrated with cefotaxime. 18 Cephalosporin (particularly second and third generation) administration is a risk factor for CDI in vivo. 42 Cephalosporin dosing aimed to simulate expected in vivo antibiotic concentrations. Pletz et al. 32 demonstrated 152 mg/kg and 258 mg/kg ceftriaxone in the faeces of patients 4 days and 8 days after commencing therapy, respectively, which is reflective of the ceftriaxone concentrations we observed in vessel 1 (if mg/kg are assumed approximately equal to mg/L). Ceftriaxone was detectable at only low concentrations in vessel 2 of the gut models (,5 mg/L) and was undetectable in vessel 3 of the gut models (data not shown). The lack of detectable bioactive ceftriaxone in the vessels of the gut model that simulate the distal colon suggests that either drug degradation/inactivation or nonspecific binding occurred. Notably, the impact of ceftriaxone on the indigenous gut microfloras was reflective of prior studies in our laboratory (S. D. Baines, G. S. Huscroft, S. L. Todhunter, J. Freeman and M. H. Wilcox, unpublished data) and also prior in vivo studies. 43 Germination of C. difficile PCR ribotype 106 and 027 spores was observed only in vessels 2 and 3 of the gut model. Ceftriaxone MICs for both strains used in the gut model experiments were 32 mg/L, and thus the supra-MIC concentrations of ceftriaxone in vessel 1 of the gut model were probably inhibitory to C. difficile proliferation and cytotoxin production. Spore germination studies using phase-contrast microscopy in our laboratory suggested that supra-MIC concentrations of antimicrobial agents may inhibit C. difficile spore outgrowth, but not germination. 44 An alternative explanation for the lack of C. difficile spore germination, proliferation and cytotoxin production in vessel 1 of the gut model could be that the more acidic (pH 5.5) conditions within this vessel were not conducive to spore germination. A recent study by Wheeldon et al. 45 investigated chemical and physical factors that may influence C. difficile spore germination; pH 6.5 -7.5 was optimum for C. difficile spore germination, and the rate and extent of germination was reduced at pH 5.5 and 8.5.
Lode et al. 33 demonstrated mean faecal concentrations of linezolid of 7.1 mg/kg (+2.6 mg/kg) in volunteers after 4 days of linezolid dosing. We therefore instilled linezolid into the gut model to achieve 7 mg/L in vessel 1. Linezolid levels differed between the two models over the first 3 days, with a substantial peak in vessel 1 concentrations on day 3 of dosing in the 027 model. This is almost certainly due to the pump malfunction described earlier. However, there was concurrence of linezolid concentrations in vessels 2 and 3. Peak linezolid concentrations and profiles in vessels 2 and 3 of both models were similar (Figure 3a and b) . There was a discrepancy between bioassay and HPLC-derived data, particularly in the 106 model, with peak levels determined by bioassay almost half those measured by HPLC (vessel 1: 7.2 versus 16.9 mg/L; vessel 2: 9.6 versus 16.7 mg/L; vessel 3: 9.2 versus 15.9 mg/L). This is within one doubling dilution and may simply be due to the bioassay operating near to its limit of detection (3 mg/L), and consequently zone sizes being difficult to measure accurately. Additional measurement by HPLC was undertaken to give better sensitivity, given the expected low concentrations of linezolid. The antimicrobial effects of linezolid against the indigenous gut microfloras within the vessels of the gut model largely reflected prior in vivo studies in healthy volunteers. 33 Obligate anaerobe populations and lactobacilli were most adversely affected by linezolid instillation, while viable counts of other facultative anaerobes (lactose-fermenting Enterobacteriaceae) increased. Declines in adversely affected bacterial groups were slow in comparison with other therapeutic agents that have been examined in the gut model (glycopeptides and metronidazole), and probably reflect the pharmacodynamic action of linezolid. Linezolid is bacteriostatic against most susceptible organisms and as such activity against the indigenous gut microfloras in the gut model would result in a slow decline in numbers. Crucially, indigenous gut microfloras within the gut model may not be actively proliferating upon commencement of antimicrobial instillation. Hence, metabolically active antimicrobials such as linezolid may potentially demonstrate reduced inhibitory activity. Upon instillation of linezolid into the model, C. difficile 46 used a simple batch culture method to demonstrate earlier toxin production and increased toxin gene transcription rates by C. difficile strains exposed to sub-MIC concentrations of metronidazole, vancomycin and linezolid, but not clindamycin. This may also indicate antimicrobial-mediated effects in C. difficile at the transcription level. We did not formally evaluate the ability of linezolid to induce C. difficile germination and toxin production in the gut model here. However, recrudescence of germination and toxin production by ribotype 106 showed post-germination toxin production by day 3, compared with day 2 following ceftriaxone induction (Figure 2a) , which is in contrast to the findings of Gerber et al. 46 This highlights the potential for conflicting results obtained in batch culture and continuous culture systems, which produce different bacterial growth dynamics; we believe that the latter are more reflective of CDI in vivo.
Linezolid concentrations differed between the gut models over the course of the initial 3 days of dosing. High peaks in vessel 1, with correspondingly low values in vessels 2 and 3 of the 027 model can be accounted for by the pump malfunction, which occurred on day 30/31. Linezolid concentrations quickly stabilized the following day and were similar to those in the 106 model for the duration of the dosing period. There was little discernible effect apart from a slight delay in detectable linezolid in vessel 3; there was no apparent effect upon C. difficile viable counts.
Following cessation of linezolid instillation viable counts of gut microflora generally increased, suggesting that linezolid does not promote sustained bacterial disruption. We observed a further cycle of C. difficile PCR ribotype 106 spore germination, proliferation and cytotoxin production following cessation of linezolid instillation. The significance and reproducibility of these observations remain to be determined. We have demonstrated a similar apparent recurrence in simulated CDI in the gut model following cessation of metronidazole instillation in C. difficile PCR ribotype 001 (UK strain) and 027 (USA strain). 23 Interestingly, we demonstrated a similar recurrence of simulated CDI following cessation of vancomycin instillation in a C. difficile PCR ribotype 027 (USA strain) experiment, but not in a comparator experiment with a UK PCR ribotype 027 strain or PCR ribotype 106 strain. 47 Whether certain C. difficile PCR ribotypes are more likely to demonstrate spore recrudescence following the removal of (therapeutic) antimicrobial pressure remains to be determined.
Results from the CDI gut model have been shown to be predictive of clinical response, i.e. exposure of C. difficile to antimicrobials with a known propensity to induce CDI in vivo (e.g. cefotaxime, clindamycin and fluoroquinolones) facilitated germination, proliferation and high-level cytotoxin production within the gut model. 18 -23 Conversely, antimicrobial agents not readily associated with development of CDI in vivo (e.g. piperacillin/tazobactam, tigecycline and mecillinam) failed to facilitate sustained C. difficile germination, proliferation and high-level cytotoxin production. 15 -17 Prior gut model experiments examining treatment agents for clindamycin-induced CDI within the gut model have included evaluations of metronidazole (C. difficile PCR ribotypes 001 and 027), vancomycin (C. difficile PCR ribotypes 001, 106 and 027), ramoplanin (C. difficile PCR ribotype 001) and tolevamer (C. difficile PCR ribotype 001). 20 -23 Given the data in the present study, further evaluation is warranted of the effect of linezolid on expression of C. difficile toxin, linezolid resistance in C. difficile and to investigate potential recurrence of CDI following removal of linezolid from the gut model.
